Alex Tkachenko

Alex Tkachenko is an accomplished Executive In Residence at EcoR1 Capital, a prominent biopharmaceutical investment firm in San Francisco.

Prior to his current role, Alex held the position of CEO at Epiodyne, a venture-backed biotech company focusing on innovative treatments for patients with addiction.

Before that, he served as the CEO of BlackThorn Therapeutics, a leading computational psychiatry organization concentrating on neurobehavioral disorders.

During his tenure at BlackThorn, Alex spearheaded remarkable achievements such as assembling a stellar team and board, securing a $40M Series A funding round from reputable investors, and establishing a cutting-edge technology platform with a robust pipeline that included a first-in-class compound already in clinical trials at the company's inception.

Alex's professional journey began at Genentech, where he played a pivotal role in the development and commercialization of groundbreaking drugs like Rituxan, Tarceva, Kadcyla, and Perjeta.

In addition to his extensive industry experience, Alex also has a unique background that includes serving as a squad leader in the Soviet Army and completing combat duty in Afghanistan.

Alex Tkachenko is a Ph.D. biologist who complemented his scientific expertise with an MBA from Harvard Business School.